A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Trial ID # NCT02889900; CONCERTO
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Cediranib, Olaparib
Eligible Participant

Platinum resistant ovarian cancer with at least 3 prior therapies

Patients Enrolled

60 non-gBRCA MUT or unk; median 4 prior therapies (3-10)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, DoR, PFS, OS, evaluated per RECIST


ORR: 15.6% (1CR, 8PR, n=59)
DCR: 23.7%
DoR: 8.3 months
PFS: 5.1 months
OS: 13.2 months

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: overall (73%)


Olaparib+cediranib has manageable toxicity and shows evidence of anti-tumor activity in heavily pretreated platinum resistant non-gBRCA MUT patients


Lee J-M et al. Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial. Clin Cancer Res (2022) 28(19):4186-4193

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.